A Study of FDA018-ADC in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the
safety, tolerability, pharmacokinetics and efficacy of FDA018-ADC in patients with
advanced/metastatic solid tumors.